Core Insights - Merit Medical (MMSI) has a strong track record of exceeding earnings estimates, particularly in the last two quarters, with an average surprise of 6.02% [1][3] - The company reported earnings of $0.86 per share for the last quarter, surpassing the Zacks Consensus Estimate of $0.80 per share by 7.50% [2] - The positive Earnings ESP of +3.03% indicates that analysts are optimistic about Merit Medical's near-term earnings potential, combined with a Zacks Rank of 2 (Buy) [6] Earnings Performance - In the previous quarter, Merit Medical's earnings were $0.92 per share against an expected $0.88, resulting in a surprise of 4.55% [2] - The favorable change in earnings estimates reflects analysts' growing confidence in the company's performance [3] Earnings ESP and Predictions - The Zacks Earnings ESP is a valuable metric that compares the Most Accurate Estimate to the Zacks Consensus Estimate, suggesting that recent analyst revisions may provide more accurate predictions [5] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [4] Upcoming Earnings Report - Merit Medical's next earnings report is anticipated to be released on February 25, 2025, and the current indicators suggest a potential earnings beat [6]

Merit Medical's Strategic Acquisitions and Market Position - The acquisition of Cook Medical's lead management portfolio is expected to enhance Merit Medical's position in the cardiac intervention market, particularly in Europe, with an estimated annual addressable opportunity of over $900 million across multiple regions [1] - The addition of the lead management business is anticipated to contribute more than $100 million in combined annualized CRM/EP revenues starting in 2025, strengthening the company's global cardiac intervention market presence [1] - The acquisition is also expected to boost Merit Medical's fast-growing, high-margin cardiac rhythm management/electrophysiology (CRM/EP) business [7] Merit Medical's Financial Performance and Guidance - Preliminary full-year 2024 revenues are estimated to be between $1.355 billion and $1.357 billion, representing a 7.7-7.9% increase from 2023 [4] - At constant currency, full-year 2024 revenues are projected to grow by 8.4-8.6% compared to 2023 [5] - The company plans to issue its full-year 2025 guidance alongside its fourth-quarter 2024 results announcement [6] Merit Medical's U.S. Market Strategy and WRAPSODY Program - The company is focused on entering the U.S. market following premarket approval, with a comprehensive U.S. commercial strategy in development [12] - Positive six-month findings from the WRAPSODY WAVE pivotal trial and progress in U.S. regulatory and reimbursement strategies highlight the potential of the WRAPSODY program [8] Merit Medical's Stock Performance and Industry Comparison - Shares of Merit Medical lost 0.9% between Oct. 1 and Dec. 31, 2024, underperforming the industry's 0.8% rise and the S&P 500's 3.7% gain [2] - Despite the short-term underperformance, the company's Zacks Rank of 2 (Buy) reflects positive sentiment [9] Industry Peers and Their Performance - Cencora (COR) has an estimated long-term growth rate of 10.4% and gained 0.2% between Oct. 1 and Dec. 31, 2024, outperforming the industry's 12.7% decline [3] - Labcorp (LH) has an estimated long-term growth rate of 8.4% and saw its shares rally 4.6% compared to the industry's 0.8% growth during the same period [3][10] - Cardinal Health (CAH) has an estimated long-term growth rate of 10.5% and gained 7.2% compared to the industry's 0.8% growth between Oct. 1 and Dec. 31, 2024 [13]

2024 preliminary unaudited revenue in the range of approximately $1.355 billion - $1.357 billion, up approximately 7.7% - 7.9% year-over-year2024 preliminary constant currency revenue* increased in the range of approximately 8.4% - 8.6% year over year2024 financial results and 2025 guidance to be released February 25, 2025 * Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable GAAP financial measure is included under the headin ...

Core Viewpoint - Merit Medical Systems, Inc. (MMSI) has received FDA premarket approval for its WRAPSODY Cell-Impermeable Endoprosthesis, which is expected to enhance its market position in the vascular intervention space and drive future revenue growth [20][19]. Company Summary - MMSI currently has a market capitalization of $5.72 billion, with fiscal 2024 revenue estimates at $1.35 billion, reflecting a 7.2% growth from fiscal 2023 [2]. - The WRAPSODY device is designed to improve long-term vessel patency in dialysis patients, addressing complications such as stenosis and thrombosis [12][4]. - The WRAPSODY WAVE pivotal trial showed promising results, with primary patency rates of 89.8% for AV fistula and 82.0% for AV graft patients at six months [13]. - Following the FDA approval announcement, MMSI's shares increased by 2.03% to $98.22, with a 29.9% gain over the past year compared to the industry’s 2.2% growth [10]. Industry Summary - The global hemodialysis market was valued at $76.9 billion in 2022 and is projected to reach $111.8 billion by 2032, growing at a CAGR of 3.8% [21]. - The need for improved dialysis access solutions is underscored by the prevalence of chronic cardiac diseases and end-stage renal disease, driving demand for advanced medical devices like the WRAPSODY [21][22]. - The FDA approval of the WRAPSODY device positions Merit Medical to capitalize on the growing market for vascular interventions, enhancing its competitive edge and opening new revenue streams [19].

Core Insights - Merit Medical Systems, Inc. has received premarket approval from the US FDA for the WRAPSODY Cell-Impermeable Endoprosthesis, allowing for commercialization in the USA starting in 2025 [6] - The WRAPSODY device is designed to improve long-term vessel patency in hemodialysis patients, addressing common issues such as stenosis and thrombosis [12][19] - Clinical trial results indicate high efficacy of the WRAPSODY device, with primary patency rates of 89.8% for AV fistula and 82.0% for AV graft patients at six months [18] Company Overview - Merit Medical, founded in 1987, specializes in the development, manufacture, and distribution of proprietary disposable medical devices for interventional, diagnostic, and therapeutic procedures [10] - The company employs approximately 7,200 individuals globally and serves hospitals worldwide with a dedicated sales force and clinical support team [10] Product Details - The WRAPSODY device features a unique design with a nitinol stent frame and a multi-layer structure aimed at reducing tissue accumulation and improving blood flow [7][12] - The device is indicated for use in treating stenosis or occlusion in the dialysis access outflow circuit, specifically in peripheral veins of individuals with AV fistulas and at the venous anastomosis of synthetic AV grafts [11] Market Context - In the United States, approximately 687,000 procedures are performed annually to maintain dialysis access, with nearly 100,000 involving stent placement [17] - The WRAPSODY device is expected to set a new standard of care in the treatment of vascular access complications for dialysis patients, as indicated by the positive outcomes from the WAVE trial [19]

SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Me ...

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Merit Medical (MMSI) or West Pharmaceutical Services (WST) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Sty ...

Merit Medical Systems, Inc. (MMSI) announced positive six-month findings from the single-arm Arteriovenous Graft (AVG) cohort of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial yesterday. The WAVE trial was designed to assess the efficacy and safety of the WRAPSODY device.The WRAPSODY Cell-Impermeable Endoprosthesis is currently not approved or available for commercial distribution in the United States. It may also not be approved or available for sale or use in other countries. However, the ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Sty ...

Merit Medical Systems, Inc. (MMSI) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 37.9% compared with the industry’s growth of 3.6%. The S&P 500 composite has risen 24% in the same period.With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.Merit Medical specializes in providing products for peripheral and cardiac interventions, targeting conditions in interve ...